Antibe Therapeutics Inc. (ATBPF)

0.2156 0.0000 (0.00%) At close: 03:46PM EDT

Antibe Therapeutics Inc.

15 Prince Arthur Avenue
Toronto, ON M5R 1B2
Canada
416-922-3460
https://www.antibethera.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel Marcel Legault J.D., L.L.B.	President, CEO & Secretary	545.18k	N/A	1958
Mr. Alain Wilson M.B.A., MBA	Chief Financial Officer	152.7k	N/A	N/A
Mr. Scott Curtis C.F.A., M.Eng	Chief Operating Officer	216.96k	N/A	N/A
Dr. David James Vaughan Ph.D.	Chief Development Officer	297.66k	N/A	1950
Dr. Joseph Stauffer D.O., M.B.A.	Chief Medical Officer	812.59k	N/A	1966
Dr. Ana Stegic	Executive Director of Clinical Operations	188.64k	N/A	N/A
Ms. Christina Cameron B.B.A.	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Philip Stern	Vice President of Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Corporate governance

Antibe Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.